TEL: (212)616-4899
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ampio Pharmaceuticals, Inc. who purchased common stock between December 29, 2020 and August 3, 2022.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Ampio Pharmaceuticals public statements were materially false and misleading at all relevant times.
Shareholders have until October 17, 2022 to request that the court appoint them lead plaintiff. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
The shareholder rights law firm Robbins LLP reminds investors that it filed a class action lawsuit against the Company and a few of the Company’s senior executives for, among other things, violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. securities laws on behalf of all individuals who purchased or otherwise acquired Ampio Pharmaceuticals, Inc. (“Ampio”) (NYSE American: AMPE) common stock between December 29, 2020 and August 3, 2022. The Securities and Exchange Commission subsequently issued Rule 10b-5.
Ampio Pharmaceuticals’ common stock trading has been halted as a result, and legal action to delist the company from the exchange has been started. Given the close closeness of this ruling to the impending stockholder meeting on October 13, 2022, we are currently weighing all of our alternatives, including an appeals procedure.
We must continue to draw in and keep excellent people if we are to meet our company’s objectives and expectations. Ampio Pharmaceuticals, Inc. strives to offer a secure and fulfilling environment with chances for our employees to grow and develop in their careers, supported by competitive pay and benefits, to help with talent attraction and retention. For instance, beginning January 1, 2022, we will cover 100% of our employees’ medical coverage and offer a Company 401(k) employer matching contribution. Additionally, we have a flexible paid time off (PTO) policy in place since we think it is important for our employees to strike a healthy work-life balance.
Ampio Pharmaceuticals strives to be a cutting-edge medication discovery and development firm that combines manufacturing, clinical, and scientific expertise to create cutting-edge therapeutics for the treatment of ailments for which there are few available treatments.
Ampio Pharmaceuticals Inc., a biopharmaceutical company, said that it has fired two executive executives and reorganized its board of directors after a special committee looked into the statistical analysis of one of its clinical studies.
Ampio Pharmaceuticals, Inc. creates cutting-edge, unique medications for inflammation, ocular, kidney, CNS, metabolic, and male erectile dysfunction. The product pipeline consists of fresh applications for medicines that have already received approval as well as novel molecular entities (“NMEs”). Focusing on finding new applications for medicines that have already received approval helps to shorten approval timelines, lower costs, and lower the risk of clinical failure because these medicines have a high likelihood of being safe and effective, and their quicker development times can result in a significant increase in near-term value.
To learn more and keep informed, complete this form >
